<DOC>
	<DOC>NCT01238835</DOC>
	<brief_summary>A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; "study valve"), the next generation Ascendra™ transapical delivery system, and crimper accessories.</brief_summary>
	<brief_title>Placement of Aortic Balloon Expandable Transcatheter Valves Trial (TransApical)</brief_title>
	<detailed_description>Purpose: The purpose of this trial is to evaluate the acute safety and effectiveness of the SAPIEN XT™ study valve and next generation Ascendra™ delivery components. Follow-up Intervals: Subject data collection will include clinical information at baseline and during the index procedure. Subjects will undergo clinical follow-up at discharge, 30 days, 6 month annually for 5 years.</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Inclusion: 1. EuroSCORE of ≥ 15 % 2. Severe senile degenerative aortic valve stenosis 3. Symptomatic aortic valve stenosis 4. Informed consent 5. Compliance Exclusion: 1. Logistic Euroscore &gt; 40 % 2. Evidence of an acute myocardial infarction 3. Congenital unicuspid or congenital bicuspid valve/ noncalcified 4. Mixed aortic valve disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sapien XT Valve</keyword>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Heart Valve Therapy</keyword>
	<keyword>Transapical</keyword>
	<keyword>Transcatheter</keyword>
</DOC>